Namandje Bumpus Sells 4,386 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 4,386 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $3.54, for a total transaction of $15,526.44. Following the completion of the sale, the director directly owned 43,171 shares in the company, valued at approximately $152,825.34. This trade represents a 9.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX traded up $0.33 during mid-day trading on Thursday, hitting $3.80. The stock had a trading volume of 38,573,526 shares, compared to its average volume of 17,309,813. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $3.29 and a 200-day simple moving average of $3.82. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -3.17 and a beta of 1.04. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same quarter in the prior year, the firm earned ($0.50) EPS. Recursion Pharmaceuticals’s quarterly revenue was down 56.8% on a year-over-year basis. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RXRX has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Morgan Stanley lifted their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, JPMorgan Chase & Co. cut their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of RXRX. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after acquiring an additional 7,407,606 shares during the last quarter. State Street Corp grew its holdings in shares of Recursion Pharmaceuticals by 38.7% in the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after acquiring an additional 7,064,963 shares during the last quarter. Norges Bank acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $23,473,000. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after acquiring an additional 3,771,357 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $7,370,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.